Literature DB >> 28345481

Cost-effectiveness analysis of implementing an antimicrobial stewardship program in critical care units.

Jesus Ruiz-Ramos1, Juan Frasquet2, Eva Romá3, Jose Luis Poveda-Andres3, Miguel Salavert-Leti4, Alvaro Castellanos1, Paula Ramirez1.   

Abstract

AIMS: To evaluate the cost-effectiveness of antimicrobial stewardship (AS) program implementation focused on critical care units based on assumptions for the Spanish setting.
MATERIALS AND METHODS: A decision model comparing costs and outcomes of sepsis, community-acquired pneumonia, and nosocomial infections (including catheter-related bacteremia, urinary tract infection, and ventilator-associated pneumonia) in critical care units with or without an AS was designed. Model variables and costs, along with their distributions, were obtained from the literature. The study was performed from the Spanish National Health System (NHS) perspective, including only direct costs. The Incremental Cost-Effectiveness Ratio (ICER) was analysed regarding the ability of the program to reduce multi-drug resistant bacteria. Uncertainty in ICERs was evaluated with probabilistic sensitivity analyses.
RESULTS: In the short-term, implementing an AS reduces the consumption of antimicrobials with a net benefit of €71,738. In the long-term, the maintenance of the program involves an additional cost to the system of €107,569. Cost per avoided resistance was €7,342, and cost-per-life-years gained (LYG) was €9,788. Results from the probabilistic sensitivity analysis showed that there was a more than 90% likelihood that an AS would be cost-effective at a level of €8,000 per LYG. LIMITATIONS: Wide variability of economic results obtained from the implementation of this type of AS program and short information on their impact on patient evolution and any resistance avoided.
CONCLUSIONS: Implementing an AS focusing on critical care patients is a long-term cost-effective tool. Implementation costs are amortized by reducing antimicrobial consumption to prevent infection by multidrug-resistant pathogens.

Entities:  

Keywords:  Anti-infective agents; Antimicrobial stewardship; Bacterial infection; Drug resistance

Mesh:

Year:  2017        PMID: 28345481     DOI: 10.1080/13696998.2017.1311903

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  6 in total

1.  Impact of an antimicrobial stewardship program on urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.

Authors:  E Esteve-Palau; S Grau; S Herrera; L Sorlí; M Montero; C Segura; X Durán; J P Horcajada
Journal:  Rev Esp Quimioter       Date:  2018-03-09       Impact factor: 1.553

2.  Implementation of a Health-System Wide Antimicrobial Stewardship Program in Omaha, NE.

Authors:  Jennifer Anthone; Dayla Boldt; Bryan Alexander; Cassara Carroll; Sumaya Ased; David Schmidt; Renuga Vivekanandan; Christopher J Destache
Journal:  Pharmacy (Basel)       Date:  2019-11-25

3.  The Impact Of Pharmaceutical Interventions On The Use Of Carbapenems In A Chinese Hospital: A Pre-Post Study.

Authors:  Chuanwei Xin; Zhongni Xia; Gonghua Li
Journal:  Infect Drug Resist       Date:  2019-11-15       Impact factor: 4.003

4.  Effectiveness of Antimicrobial Stewardship Program in Long-Term Care: A Five-Year Prospective Single-Center Study.

Authors:  Maha Mahmoud Alawi; Wail A Tashkandi; Mohamed A Basheikh; Faten M Warshan; Hazem Ahmed Ghobara; Rosemarie B Ramos; Mary Leilani Guiriba; Omar Ayob; Safiah Saad Janah; Anees Ahmad Sindi; Suheib Ali Abdulhamid Ahmed; Salah Dammnan; Esam Ibraheem Azhar; Ali A Rabaan; Salma Alnahdi; Maged Mohammed Bamahakesh
Journal:  Interdiscip Perspect Infect Dis       Date:  2022-04-12

Review 5.  Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs: A Narrative Review.

Authors:  Fazlollah Keshavarzi
Journal:  Iran J Med Sci       Date:  2022-09

6.  Antibiotic prophylaxis in the ICU: to be or not to be administered for patients undergoing procedures?

Authors:  Ignacio Martin-Loeches; Marc Leone; Sharon Einav
Journal:  Intensive Care Med       Date:  2019-11-28       Impact factor: 17.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.